Artificial intelligence and digital health in global eye health: opportunities and challenges.

Journal: The Lancet. Global health
Published Date:

Abstract

Global eye health is defined as the degree to which vision, ocular health, and function are maximised worldwide, thereby optimising overall wellbeing and quality of life. Improving eye health is a global priority as a key to unlocking human potential by reducing the morbidity burden of disease, increasing productivity, and supporting access to education. Although extraordinary progress fuelled by global eye health initiatives has been made over the last decade, there remain substantial challenges impeding further progress. The accelerated development of digital health and artificial intelligence (AI) applications provides an opportunity to transform eye health, from facilitating and increasing access to eye care to supporting clinical decision making with an objective, data-driven approach. Here, we explore the opportunities and challenges presented by digital health and AI in global eye health and describe how these technologies could be leveraged to improve global eye health. AI, telehealth, and emerging technologies have great potential, but require specific work to overcome barriers to implementation. We suggest that a global digital eye health task force could facilitate coordination of funding, infrastructural development, and democratisation of AI and digital health to drive progress forwards in this domain.

Authors

  • Ting Fang Tan
    Singapore National Eye Center, Singapore Eye Research Institute Singapore Health Service Singapore Singapore.
  • Arun J Thirunavukarasu
    Artificial Intelligence and Digital Innovation Research Group, Singapore Eye Research Institute, Singapore; Corpus Christi College, University of Cambridge, Cambridge, UK; School of Clinical Medicine, University of Cambridge, Cambridge, UK.
  • Liyuan Jin
    Duke-NUS Medical School, Singapore, Singapore.
  • Joshua Lim
    Artificial Intelligence and Digital Innovation Research Group, Singapore Eye Research Institute, Singapore; Singapore National Eye Centre, Singapore General Hospital, Singapore.
  • Stanley Poh
    Artificial Intelligence and Digital Innovation Research Group, Singapore Eye Research Institute, Singapore; Singapore National Eye Centre, Singapore General Hospital, Singapore.
  • Zhen Ling Teo
    Singapore Eye Research Institute, Singapore National Eye Centre, Singapore.
  • Marcus Ang
    Singapore National Eye Centre, Singapore, Singapore.
  • R V Paul Chan
    Ophthalmology, Illinois Eye and Ear Infirmary, Chicago, IL, United States.
  • Jasmine Ong
    Pharmacy Department, Singapore General Hospital, Singapore.
  • Angus Turner
    Lions Eye Institute, 2 Verdun St, Perth, Australia.
  • Jonas Karlström
    Duke-NUS Medical School, National University of Singapore, Singapore.
  • Tien Yin Wong
    Singapore National Eye Center, Duke-National University of Singapore Medical School, Singapore 168751, Singapore; National Institutes of Health Research Biomedical Research Centre Biomedical Centre, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.
  • Jude Stern
    The International Agency for the Prevention of Blindness, London, UK.
  • Daniel Shu-Wei Ting
    Artificial Intelligence and Digital Innovation Research Group, Singapore Eye Research Institute, Singapore; Singapore National Eye Centre, Singapore General Hospital, Singapore; Duke-NUS Medical School, National University of Singapore, Singapore. Electronic address: daniel.ting@duke-nus.edu.sg.